（来源：一度医药） 转自：一度医药 2024年，辉凌在芬兰库奥皮奥新建了一座生产工厂，专门用于为基因治疗药物Adstiladrin生产原料药。 Adstiladrin是Ferring的重要战略产品，于2022年底获美国FDA批准上市，是全球首个针对"对现有治疗无 响应的高危非肌层浸润性膀胱癌"的基因疗法，此次新建工厂也为该药物的产能保障与全球供应奠定了 基础。 对于重组后的发展方向，辉凌在本周的声明中进一步明确：未来将持续加大对"现代技术"的投入，并将 业务开发重点放在"中后期机会"上。这一规划暗示，公司可能会减少对早期研发的分散投入，转而聚焦 于更接近商业化、风险相对可控的项目，以提升资源利用效率，加速创新成果的落地转化。 值得注意的是，此次裁员并非辉凌首次进行人员优化。 2024年，辉凌已先后在两个核心业务站点实施过裁员：先是在美国新泽西州帕西帕尼的美国总部裁撤79 个岗位，后又在明尼苏达州罗斯维尔的微生物组研究中心削减55个职位，全年累计裁员134人； 2023年，辉凌还关闭了位于美国圣地亚哥的研究机构，导致89名员工失去工作。连续数年的人员调整， 折射出公司在业务布局上的持续收缩与聚焦，逐步剥离非核心 ...

Group 1 - The core viewpoint is that Kaili New Materials (688269.SH) has announced an increase in uncertainty regarding the future operating conditions of Kaili Platinum, influenced by various factors such as market environment, macroeconomic conditions, and partners [1] - Kaili Platinum has not commenced any actual business activities, and shareholders have not contributed their capital [1] - To optimize resources, improve asset operation efficiency, and reduce management costs, the company plans to deregister Kaili Platinum after friendly consultations with all shareholders [1]

Group 1 - The China Securities Association has initiated the 2024 annual operating data statistics for 107 domestic securities firms to analyze industry performance and provide accurate data for regulatory decisions [1] - The statistics will focus on various dimensions including branch efficiency, wealth management dynamics, revenue structure, and cross-border business expansion, with specific indicators related to securities trading income and asset management [1] - The statistical work is launched against the backdrop of significant recovery in the securities industry, aiming to clarify business transformation effectiveness, risk distribution, and resource optimization [1] Group 2 - According to the China Securities Association, the entire industry is projected to achieve operating income of 451.17 billion yuan and net profit of 167.26 billion yuan in 2024, representing year-on-year growth of 11.2% and 21.3% respectively [2] - Proprietary trading income is expected to be 174.07 billion yuan, accounting for 38.6% of total income, and it has the highest year-on-year growth rate among major business segments at 43.0% [2]

Overview - Xi'an Global Printing Co., Ltd. has decided to shrink its internet digital marketing segment to enhance overall operational efficiency and optimize resource allocation, focusing on core strategic directions in response to market uncertainties and pressures [1][2]. Business Adjustment - The board of directors approved the proposal to suspend the internet digital marketing business of its subsidiary, aiming to refine the company's business layout and improve overall efficiency [2][6]. - The decision is based on the current situation of the internet digital marketing business and market conditions, with the goal of protecting the legal rights of the company and all shareholders [2][6]. Subsidiary Information - The subsidiary, Holguozi Linkai Network Technology Co., Ltd., along with its subsidiaries, provides internet digital marketing services, including technical support, creative design, and market development assistance [2][5]. Financial Performance - The financial data indicates significant challenges, with total assets of 119.15 million and total liabilities of 291.10 million, resulting in a negative equity of -171.95 million [5]. - The subsidiary reported a net loss of 59.97 million for the audited period, highlighting the financial strain on the internet digital marketing segment [5][6]. Market Conditions - The internet and mobile internet sectors are experiencing intensified competition, leading to a decline in revenue and gross margins for the digital marketing segment, compounded by overdue accounts receivable and insufficient working capital [6][7]. - The company anticipates that the suspension of the digital marketing business will narrow its operational scope and significantly reduce revenue, impacting the financial results for 2025 [6][7]. Strategic Focus - The move to suspend the digital marketing business aligns with the company's strategic deployment and development status, allowing it to concentrate resources on core business areas and enhance competitive advantages [7]. - The company plans to strengthen debt collection efforts to protect shareholder interests following the business adjustment [7].